Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002416 · ClinicalTrials.gov registry record · Phase 3
Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination
A Phase 3 study, sponsored by Triangle Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT00002416: Completed Phase 3 study, sponsored by Triangle Pharmaceuticals.
NCT00002416 is a Phase 3 study that has completed, run by Triangle Pharmaceuticals. The registered enrollment target is 390 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002416, a Phase 3 study, has completed, sponsored by Triangle Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.
Interventions
- DRUG Lamivudine
- DRUG Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Phase | Phase 3 |
What the finished NCT00002416 record still lists
NCT00002416 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 2 interventions - of which Lamivudine is the first listed.
NCT00002416 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002416 about?
NCT00002416 is a clinical study titled "Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination". The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.
What is the current status of trial NCT00002416?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants.
What interventions are being tested in trial NCT00002416?
The interventions under investigation include: Lamivudine (DRUG), Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT00002416?
This trial is sponsored by Triangle Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002416's enrollment target sits among peer trials
390 968th of 2000 higher than 1,029 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer